Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
about
Bortezomib for the treatment of multiple myelomaFirst line vs delayed transplantation in myeloma: Certainties and controversiesEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsFifty years of melphalan use in hematopoietic stem cell transplantationTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersIncidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysisEuropean perspective on multiple myeloma treatment strategies in 2014Advances in the autologous and allogeneic transplantation strategies for multiple myelomaEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaA prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaA phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaUpdate on the optimal use of bortezomib in the treatment of multiple myelomaPharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaThe future of autologous stem cell transplantation in myeloma.Bortezomib in multiple myeloma: systematic review and clinical considerations.Minor clone provides a reservoir for relapse in multiple myelomaA phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyMechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-rApproach to the treatment of multiple myeloma: a clash of philosophies.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesCyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.European perspective on multiple myeloma treatment strategies: update following recent congressesAllogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.
P2860
Q24185881-48C1CA03-0106-4A50-81AA-45C14AF1AEDDQ26745957-28698A6E-2611-4000-96E8-FBDFC6184DE6Q26767418-1D50DD10-22BF-4215-BD14-79FE791422DDQ26822754-8D222642-F934-4BF6-93C3-FE22641BFA68Q26824498-75C59FE6-D35C-479A-A18E-317F895BC19FQ26851202-FDF372E6-2EBF-4E03-B4CF-13E17A1BF000Q26991817-45C232E5-1872-4F2F-BD60-427AFAB53B24Q27005966-949106BF-80D3-4C44-992D-B3A809B53561Q27014801-72467AF8-8FF8-4AB6-A784-F31E5A2CFE8CQ27026478-0F2F4618-94B1-4798-B410-CFA4CE9BE11EQ28075297-1F6120AC-9E2A-49BC-B81B-1A2EDCFDB787Q28077567-3E7A01B6-EFAA-4EA3-A6A6-C4E5C1878CBEQ28539605-F07B4893-CA23-4D94-9E3B-3C30E3E9F485Q30248842-8F226C95-3C14-4760-B847-35666D66A084Q30409713-AB5E2596-15FB-4FFB-8CDD-D9C565F81580Q33401596-E73AA87C-8843-4E92-80DE-9D0DDF57FD1EQ33405134-D865AD43-D1CE-4913-8C96-CF66F03D458BQ33405532-96D91964-60F7-4B87-B5BE-6482632F91EFQ33408056-D70A1F14-2962-4A8A-BF49-5289DEA2128FQ33412684-8BC6E8CA-6F0A-4CC7-AB97-6525C6C7C064Q33440007-DCB90F0D-E40D-4B48-8EE3-FA974F20B772Q33442798-A40CD735-E75A-4EBD-8926-C3F0401804C5Q33558161-34ACCC62-2E6F-4FA8-82E2-91B189BA5B1DQ33648344-5CDD0C48-5DE0-4418-9975-F1A957F678F9Q33917164-06DB63C9-3BF8-4DB3-8429-A231B77C40C5Q33982728-ED510084-BCEF-4941-A6FC-16022C42AD7EQ34147170-F085B024-EC9B-4955-A8A3-D844841B0D61Q34307050-90A42FCD-BF55-4522-ABD8-FE6F55FBDF0AQ34539519-E50799FF-E679-42B2-B56D-06792D01B8A5Q34788381-CC0CF842-05F5-4CB2-A3E6-B5CE34AEB57FQ35061518-6B03B733-AED4-4FB7-8E88-2FAF028E886AQ35171777-343F44A4-39BB-4A66-9403-8FA215224797Q35180069-EE41C009-DAE4-4491-91A6-5F1D4AF0763BQ35230189-3F91C9B7-EB64-4F46-A308-08DA405920ECQ35569350-59153F31-83ED-4B56-B8EF-286D09DCAB91Q35794472-08F50BFA-9ADC-455D-AAEB-2744B854602BQ35802414-4ABA81D1-BFB8-45E1-93DD-89E524840040Q35989943-DF2DB612-8AFB-430D-B54E-EA3697B967E8Q36000415-89B45A95-92CC-4745-B94D-34D519A554E8Q36014687-2797204E-7788-49E7-8D23-49147FDD907E
P2860
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@en
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@nl
type
label
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@en
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@nl
prefLabel
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@en
Bortezomib plus dexamethasone ...... e IFM 2005-01 phase III trial.
@nl
P2093
P50
P356
P1476
Bortezomib plus dexamethasone ...... he IFM 2005-01 phase III trial
@en
P2093
Claire Mathiot
Cyrille Hulin
Denis Caillot
Frédéric Maloisel
Gerald Marit
Hervé Maisonneuve
Jean-Luc Harousseau
Lotfi Benboubker
Marie-Odile Petillon
P304
P356
10.1200/JCO.2009.27.9158
P407
P577
2010-09-07T00:00:00Z